Prosecution Insights
Prosecution Insights
20 pending office actions • 10 art units • 17 examiners • 0 of 20 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 3 (15%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 14 (70%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANDELARIA, JULIANA IRENE | 2 | 0.0% | +0.0% |
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.7% |
| REGLAS, GILLIAN CHELSEA | 2 | 29.8% | +49.7% |
| CONNORS, ALEXANDRA F | 1 | 23.1% | +44.3% |
| LARA, CAROLINE MONSERRAT | 1 | 100.0% | +0.0% |
| DUNN, LINDSAY MICHELLE | 1 | 100.0% | +0.0% |
| NGUYEN, NGHI V | 1 | 53.4% | +50.7% |
| ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1 | — | — |
| KASAYAN, KATRIEL BARCELLANO | 1 | 33.3% | +0.0% |
| CRAIG, KAILA ANGELIQUE | 1 | 32.8% | +26.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 161d overdue |
| 18348292 | TREATMENT OF LIMB ISCHEMIA BY BONE MARROW STEM CELLS AND MODIFICATION OF DISEASED MICROENVIRONMENT | CANDELARIA, JULIANA IRENE | 80d overdue |
| 18183900 | THERAPEUTIC REGENERATIVE CELLS | REGLAS, GILLIAN CHELSEA | 73d overdue |
| 18358490 | POTENTIATION OF BONE MARROW CELL ACTIVITY BY COADMINISTRATION WITH OXYTOCIN | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 71d overdue |
| 18331048 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED ENDOTHELIAL PROGENITOR CELLS | KASAYAN, KATRIEL BARCELLANO | 50d overdue |
| 18311474 | STIMULATION OF OVARIAN FUNCTION SUBSEQUENT TO CHEMOTHERAPY AND/OR RADIATION THERAPY USING NATURAL KILLER CELLS | ALDARONDO, DASIA ALI | 42d overdue |
| 17865881 | Therapeutic Monocytic Lineage Cells | JOHNSON, ALLISON MARIE | 19d overdue |
| 18173052 | METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES | YOUTCHOM PENDIE, EMMANUEL LED | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18183900 | THERAPEUTIC REGENERATIVE CELLS | REGLAS, GILLIAN CHELSEA | 73d overdue |
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | — |
| 18315364 | EXOSOME BASED ASSAYS FOR DETERMINING CANDIDATES FOR OSTEOARTHRITIS STEM CELL THERAPY | CRAIG, KAILA ANGELIQUE | — |
| 18311768 | DEGENERATING OVARIAN MICROENVIRONMENT RESISTANT MESENCHYMAL STEM CELLS | REGLAS, GILLIAN CHELSEA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1638 | 3 |
| 1644 | 2 |
| 1634 | 2 |
| 1647 | 2 |
| 1653 | 1 |
| 1618 | 1 |
| 1796 | 1 |
| 1631 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18785132 | In Vitro and In Vivo Generation of Insulin Producing Cells | CONNORS, ALEXANDRA F | — | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18785305 | Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells | CANDELARIA, JULIANA IRENE | — | §101§102§112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | LARA, CAROLINE MONSERRAT | — | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | NGUYEN, NGHI V | 1653 | §102§103§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18358490 | POTENTIATION OF BONE MARROW CELL ACTIVITY BY COADMINISTRATION WITH OXYTOCIN | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1632 | §103§112 | Non-Final OA | 71d overdue | Pending | Jul 25, 2023 |
| 18348292 | TREATMENT OF LIMB ISCHEMIA BY BONE MARROW STEM CELLS AND MODIFICATION OF DISEASED MICROENVIRONMENT | CANDELARIA, JULIANA IRENE | 1634 | §112Other | Non-Final OA | 80d overdue | Pending | Jul 06, 2023 |
| 18331048 | GENERATION OF CONDITIONED MEDIA FROM INDUCIBLE PLURIPOTENT STEM CELL DERIVED ENDOTHELIAL PROGENITOR CELLS | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112 | Non-Final OA | 50d overdue | Pending | Jun 07, 2023 |
| 18331098 | INDUCIBLE PLURIPOTENT STEM CELL DERIVED REGENERATIVE T CELLS | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
| 18315364 | EXOSOME BASED ASSAYS FOR DETERMINING CANDIDATES FOR OSTEOARTHRITIS STEM CELL THERAPY | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | — | Pending | May 10, 2023 |
| 18311464 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 83d | Pending | May 03, 2023 |
| 18311474 | STIMULATION OF OVARIAN FUNCTION SUBSEQUENT TO CHEMOTHERAPY AND/OR RADIATION THERAPY USING NATURAL KILLER CELLS | ALDARONDO, DASIA ALI | 1647 | §103§112 | Non-Final OA | 42d overdue | Pending | May 03, 2023 |
| 18311768 | DEGENERATING OVARIAN MICROENVIRONMENT RESISTANT MESENCHYMAL STEM CELLS | REGLAS, GILLIAN CHELSEA | 1632 | §103§112DP | Final Rejection | — | Pending | May 03, 2023 |
| 18311445 | CYTOKINE BASED ASSESSMENT OF RECIPIENT ABILITY TO RESPOND TO STEM CELL THERAPY FOR CARTILAGE REGENERATION | KUMAR, SRILAKSHMI K | 1796 | §102§103 | Non-Final OA | 9d overdue | Pending | May 03, 2023 |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | 161d overdue | Pending | Apr 13, 2023 |
| 18183900 | THERAPEUTIC REGENERATIVE CELLS | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | 73d overdue | Pending | Mar 14, 2023 |
| 18173052 | METHODS FOR QUANTIFYING POTENCY OF REGENERATIVE IMMUNOTHERAPIES | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §102§103 | Non-Final OA | 17d overdue | Pending | Feb 22, 2023 |
| 18082841 | CHIMERIC ANTIGEN RECEPTOR REGENERATIVE GAMMA DELTA T CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103Other | Final Rejection | 21d | Pending | Dec 16, 2022 |
| 17865881 | Therapeutic Monocytic Lineage Cells | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Non-Final OA | 19d overdue | Pending | Jul 15, 2022 |
| 17585356 | TREATMENT OF KIDNEY FAILURE USING EX VIVO REPROGRAMMED IMMUNE CELLS | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | 7d | Pending | Jan 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial